Evidence map›Paper›PMID 42835945›Full record

ArticleJournal of structural biology: X2026

Evolutionary and structural pathways of antibody maturation reveal principles for engineering potent SARS-CoV-2 neutralizers.

Muhammad Waqas Nasir, Qiyun Liang, Jing Wang, Yan Sun, Xiangyu Zhang, Rishen Liang, Jun He, Umer Rashid, Jiabing Wu, Yong Gao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of structural biology: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Muhammad Waqas NasirThe First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, China.
Qiyun LiangThe First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, China.
Jing WangThe First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, China.
Yan SunDepartment of Chemistry, University of Science and Technology of China, Hefei, Anhui 230001, China.
Xiangyu ZhangThe First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, China.
Rishen LiangThe First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, China.
Jun HeAnhui Provincial Center for Disease Control and Prevention, Hefei 230601, China.
Umer RashidDepartment of Chemistry, COMSATS University, Islamabad, Abbottabad Campus, 22060 Abbottabad, Pakistan.
Jiabing WuAnhui Provincial Center for Disease Control and Prevention, Hefei 230601, China.
Yong GaoThe First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The continual emergence of SARS-CoV-2 variants underscores the need to elucidate antibody maturation and apply rational design principles to optimize therapeutics. This study focused on vaccine-elicited 9C lineage, encoded by IGHV4-34, as a model for affinity maturation and structural refinement. Sequence analyses revealed strong framework conservation alongside focused diversification within CDRH3, where the invariant RWFD anchor and a recurrent SYTV block were consistently associated with potent neutralization. Phylogenetic reconstruction traced a trajectory from weakly neutralizing precursors, such as 9A91, to ultrapotent clones, like 9C2, showing nearly a 3000-fold improvement in IC₅₀ values. Computational modeling, molecular dynamics, and docking analyses demonstrated that potency arises from progressive stabilization of the CDRH3 apex, with the SYT motif at VH106-108 serving as a critical structural driver with improved IC

Indexed as

Affinity maturationAntibody engineeringCDRH3 somatic hypermutationIGHV4–34 lineageSARS-CoV-2SYP cap

Identifiers

PMID42835945
PMCPMC13636076

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.